Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia

B. Burkhardt, D. Yavuz, M. Zimmermann, J. Schieferstein, E. Kabickova, A. Attarbaschi, J. Lisfeld, A. Reiter, O. Makarova, J. Worch, BR. Bonn, C. Damm-Welk,

. 2016 ; 95 (9) : 1503-12. [pub] 20160704

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013727

Recent studies in adult lymphoma patients have indicated a correlation between polymorphisms of Fc gamma-receptors (FcγRs, encoded by the respective FCGR genes) and the response to rituximab treatment. In vitro, cells expressing FcγRIIIa-158V mediate antibody-dependent cellular cytotoxicity (ADCC) more efficiently than cells expressing FcγRIIIa-158F. The impact of the FCGR2A-131HR polymorphism is unclear. In this study, the FCGR polymorphisms FCGR3A-158VF and FCGR2A-131HR were analyzed in pediatric patients with mature aggressive B cell non-Hodgkin lymphoma/leukemia (B-NHL). Pediatric patients received a single dose of rituximab monotherapy. Response was evaluated on day 5 followed by standard chemotherapy for B-NHL. Among 105 evaluable patients, a response to rituximab was observed in 21 % of those homozygous for FcγRIIa-131RR (5/24) compared to 48 % of patients who were HH and HR FcγRIIa-131 allele carriers (18/34 and 21/47, respectively; p = 0.044). Among patients with the FCGR3A-158 polymorphism, those homozygous for the FF genotype had a significantly favorable rituximab response rate of 59 % (22/37) compared to 32 % in patients who were FcγRIIIa-158VV and FcγRIIIa-VF allele carriers (2/9 and 20/59, respectively; p = 0.022). A stringent phase II response evaluation of children and adolescents with B-NHL after one dose of rituximab monotherapy showed a significant association between the rituximab response rate and FCGR polymorphisms. These findings support the hypothesis that FCGR polymorphisms represent patient-specific parameters that influence the response to rituximab.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013727
003      
CZ-PrNML
005      
20170425122444.0
007      
ta
008      
170413s2016 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-016-2731-x $2 doi
035    __
$a (PubMed)27376362
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Burkhardt, Birgit $u Pediatric Hematology and Oncology, NHL-BFM Study Center, University Children's Hospital Muenster, Domagkstrasse 24, D-48149, Muenster, Germany. birgit.burkhardt@ukmuenster.de.
245    10
$a Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia / $c B. Burkhardt, D. Yavuz, M. Zimmermann, J. Schieferstein, E. Kabickova, A. Attarbaschi, J. Lisfeld, A. Reiter, O. Makarova, J. Worch, BR. Bonn, C. Damm-Welk,
520    9_
$a Recent studies in adult lymphoma patients have indicated a correlation between polymorphisms of Fc gamma-receptors (FcγRs, encoded by the respective FCGR genes) and the response to rituximab treatment. In vitro, cells expressing FcγRIIIa-158V mediate antibody-dependent cellular cytotoxicity (ADCC) more efficiently than cells expressing FcγRIIIa-158F. The impact of the FCGR2A-131HR polymorphism is unclear. In this study, the FCGR polymorphisms FCGR3A-158VF and FCGR2A-131HR were analyzed in pediatric patients with mature aggressive B cell non-Hodgkin lymphoma/leukemia (B-NHL). Pediatric patients received a single dose of rituximab monotherapy. Response was evaluated on day 5 followed by standard chemotherapy for B-NHL. Among 105 evaluable patients, a response to rituximab was observed in 21 % of those homozygous for FcγRIIa-131RR (5/24) compared to 48 % of patients who were HH and HR FcγRIIa-131 allele carriers (18/34 and 21/47, respectively; p = 0.044). Among patients with the FCGR3A-158 polymorphism, those homozygous for the FF genotype had a significantly favorable rituximab response rate of 59 % (22/37) compared to 32 % in patients who were FcγRIIIa-158VV and FcγRIIIa-VF allele carriers (2/9 and 20/59, respectively; p = 0.022). A stringent phase II response evaluation of children and adolescents with B-NHL after one dose of rituximab monotherapy showed a significant association between the rituximab response rate and FCGR polymorphisms. These findings support the hypothesis that FCGR polymorphisms represent patient-specific parameters that influence the response to rituximab.
650    _2
$a mladiství $7 D000293
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a frekvence genu $7 D005787
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    _2
$a L-laktátdehydrogenasa $x krev $x metabolismus $7 D007770
650    _2
$a B-buněčný lymfom $x krev $x farmakoterapie $x genetika $7 D016393
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a multivariační analýza $7 D015999
650    _2
$a lokální recidiva nádoru $7 D009364
650    12
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a prognóza $7 D011379
650    _2
$a receptory IgG $x genetika $7 D017452
650    _2
$a indukce remise $7 D012074
650    _2
$a rituximab $x terapeutické užití $7 D000069283
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Yavuz, Deniz $u Pediatric Hematology and Oncology, NHL-BFM Study Center, Justus Liebig University Giessen, Giessen, Germany.
700    1_
$a Zimmermann, Martin $u Pediatric Hematology and Oncology, NHL-BFM Study Center, University Children's Hospital Muenster, Domagkstrasse 24, D-48149, Muenster, Germany.
700    1_
$a Schieferstein, Jutta $u Pediatric Hematology and Oncology, NHL-BFM Study Center, Justus Liebig University Giessen, Giessen, Germany.
700    1_
$a Kabickova, Edita $u Department of Pediatric Hematology and Oncology, Charles University, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Attarbaschi, Andishe $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria. $7 gn_A_00009851
700    1_
$a Lisfeld, Jasmin $u Pediatric Hematology and Oncology, NHL-BFM Study Center, Justus Liebig University Giessen, Giessen, Germany.
700    1_
$a Reiter, Alfred $u Pediatric Hematology and Oncology, NHL-BFM Study Center, Justus Liebig University Giessen, Giessen, Germany.
700    1_
$a Makarova, Olga $u Pediatric Hematology and Oncology, NHL-BFM Study Center, University Children's Hospital Muenster, Domagkstrasse 24, D-48149, Muenster, Germany.
700    1_
$a Worch, Jennifer $u Pediatric Hematology and Oncology, NHL-BFM Study Center, University Children's Hospital Muenster, Domagkstrasse 24, D-48149, Muenster, Germany.
700    1_
$a Bonn, Bettina R $u Pediatric Hematology and Oncology, NHL-BFM Study Center, University Children's Hospital Muenster, Domagkstrasse 24, D-48149, Muenster, Germany.
700    1_
$a Damm-Welk, Christine $u Pediatric Hematology and Oncology, NHL-BFM Study Center, Justus Liebig University Giessen, Giessen, Germany.
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 95, č. 9 (2016), s. 1503-12
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27376362 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170425122801 $b ABA008
999    __
$a ok $b bmc $g 1200192 $s 974505
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 95 $c 9 $d 1503-12 $e 20160704 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace